Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksNovacyt Share News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 66.20
Bid: 64.20
Ask: 67.00
Change: -1.80 (-2.65%)
Spread: 2.80 (4.361%)
Open: 66.00
High: 66.40
Low: 64.00
Prev. Close: 68.00
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Novacyt trading in line as it seeks fresh funding

Tue, 26th Feb 2019 15:47

(Sharecast News) - Clinical diagnostics specialist Novacyt updated the market on its current position and funding plans on Tuesday, confirming that 2019 trading had started positively and was in line with 2019 management expectations.The AIM-traded firm said it was also continuing to make progress with the ongoing negotiations in relation to the sale of the 'NOVAprep' and the Clinical Lab businesses, and would continue to update the market as the transactions progressed.It said its cash position as at 22 February was approximately €0.95m, which was ahead of plan, with the board saying it was currently in advanced discussions with debt providers in relation to a material investment, of which it said a "significant proportion" would be used to consolidate its current debt obligations."The company expects to complete this financing within the next six to eight weeks," the board said in its statement."Although there can be no guarantee in respect of the amount that can be raised, the preference of the company is to target the raising of funds in the least dilutive form for shareholders."Further announcements will be made as appropriate in due course."
More News
29 Jun 2021 09:03

Novacyt launches two new rapid Covid-19 test products

(Sharecast News) - Clinical diagnostics specialist Novacyt announced the planned launch of two 'PathFlow' Covid-19 antigen lateral flow tests on Tuesday, to strengthen its Covid-19 portfolio and to pursue significant new market opportunities, particularly in point-of-care settings.

Read more
22 Jun 2021 08:46

Novacyt swings to huge profit after pivot to Covid test portfolio

(Sharecast News) - Clinical diagnostics specialist Novacyt announced a more-than-twentyfold improvement in group consolidated revenue in its full-year results on Tuesday, to £277.2m, as its gross margin improved to 76.3% in 2020, from 64% in 2019.

Read more
17 May 2021 09:16

Novacyt test for variants of concern included in NHS framework

(Sharecast News) - Clinical diagnostics company Novacyt announced on Monday that its 'SNPsig' SARS-CoV-2 polymerase chain reaction (PCR) genotyping portfolio has been included in the NHS England framework for detecting Covid-19 'variants of concern'.

Read more
23 Apr 2021 16:28

Novacyt makes progress with Covid-19 programmes

(Sharecast News) - Clinical diagnostics specialist Novacyt updated the market on the progress of its near-term Covid-19 research and development programmes on Friday, addressing "rapidly-evolving" testing demands, particularly as SARS-CoV-2 continued to mutate globally.

Read more
9 Apr 2021 15:23

Novacyt dispute with DHSC to dent 2021 profit, shares slide

(Sharecast News) - Novacyt said on Friday that a dispute with the Department of Health and Social Care (DHSC) over a supply contract could have a "material" impact on fourth-quarter revenues and dent 2021 profit and revenue, sending its shares sharply lower.

Read more
24 Mar 2021 10:02

Novacyt launches CE-marked rapid Covid-19 variant test

(Sharecast News) - Clinical diagnostics specialist Novacyt announced the launch of 'SNPsig VariPLEX' on Wednesday, as a CE-marked polymerase chain reaction (PCR) assay panel, able to detect the four currently-recognised Covid-19 variants of concern, and the two most biologically significant mutations, in a single kit.

Read more
17 Mar 2021 08:32

Novacyt launches mobile Covid-19 testing labs

(Sharecast News) - Clinical diagnostics specialist Novacyt announced the expansion of its 'VersaLab' service on Wednesday, with the launch of mobile processing laboratories to provide rapid turnaround polymerase chain reaction (PCR) testing on-site.

Read more
24 Feb 2021 11:35

Covid-19 testing focus underpinning progress at Novacyt

(Sharecast News) - Clinical diagnostics company Novacyt updated the market on the progress of its near-term research and development programmes on Wednesday, including the expansion of its product portfolio, clinical trial activity and the publication of independent validations of its Covid-19 tests.

Read more
2 Feb 2021 09:08

Novacyt launches new Covid-19 test assays for variant strains

(Sharecast News) - Clinical diagnostics company Novacyt announced the launch of a new portfolio of assays under the brand name 'SNPsig' on Tuesday, to aid the diagnosis of the new variants of SARS-CoV-2, the virus which causes the Covid-19 disease.

Read more
29 Jan 2021 09:43

Novacyt FY revenues surge on demand for Covid-19 products

(Sharecast News) - Clinical diagnostics firm Novacyt said on Friday that full-year revenues had surged in 2020, driven by the continued successful global commercialisation of its Covid-19 product portfolio.

Read more
5 Jan 2021 10:53

Novacyt taps James McCarthy as new CFO

(Sharecast News) - Clinical diagnostics company Novacyt announced on Tuesday that James McCarthy has been appointed as chief financial officer, while Anthony Dyer has taken on a new role as chief corporate development officer (CCDO).

Read more
21 Dec 2020 10:07

Novacyt says its tests can detect new Covid strain, shares surge

(Sharecast News) - Novacyt shares surged on Monday after the clinical diagnostics specialist said that its tests can detect the new strain of Covid-19 identified by the UK's Genomics consortium, known as VUI-202012/01.

Read more
14 Dec 2020 16:16

Novacyt releases new tests for Covid-19, bird flu

(Sharecast News) - Clinical diagnostics company Novacyt announced the launch of its research-use-only polymerase chain reaction test for a new strain of Covid-19 on Monday, as well as the development of two new research-use0only polymerase chain reaction tests for avian influenza, following recent outbreaks across Europe.

Read more
17 Sep 2020 08:15

Novacyt swings to profit on soaring Covid test sales

(Sharecast News) - Covid-19 test maker Novacyt swung to a first-half profit driven by soaring sales during the current pandemic and said it expected core annual earnings to top €100m.

Read more
4 Sep 2020 10:37

Novacyt launches two-gene target test for Covid-19

(Sharecast News) - Clinical diagnostics company Novacyt announced on Friday that it has launched a CE-marked polymerase chain reaction (PCR) two-gene target test for Covid-19.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.